Background {#Sec1}
==========

Prevalence of obesity continues to increase worldwide, mainly as a result of changing lifestyles. It is known that visceral fat-type obesity induces type-2 diabetes mellitus, hyperlipidaemia, hypertension and increases the risk of cardiovascular disease \[[@CR1]--[@CR3]\]. Subcutaneous fat-type obesity is associated with excessive weight gain, and is thought to be the main risk factor for osteoarthritis of the knee \[[@CR4]--[@CR7]\], sleep apnoea \[[@CR8]\], and menstrual abnormalities \[[@CR9]--[@CR11]\]. Consequently, research on the prevention and treatment of obesity has been expanded.

Glucosyl hesperidin (G-hesperidin) is synthesized by enzymatic means from hesperidin purified from oranges (*Citrus aurantium*) and dextrin. Its solubility in water is over 10,000-fold greater than that of hesperidin \[[@CR12]\]. G-hesperidin has been reported to reduce serum levels of triglyceride (TG) in animals \[[@CR13]--[@CR15]\] and subjects with hypertriglyceridemia \[[@CR16], [@CR17]\]. The mechanism of the TG-lowering effect of G-hesperidin is thought to be down-regulation of the synthesis/secretion of very-low-density lipoprotein in hepatocytes \[[@CR18]\], inhibition of lipogenesis, and induction of beta oxidation of fatty acids in high-fat diet-fed rats \[[@CR15]\]. Studies have shown that daily intake of G-hesperidin (500 mg) in subjects with a moderately high BMI for 12 weeks decreases abdominal fat significantly during the period, but these decreases do not differ significantly from those of subjects taking a placebo \[[@CR19]\]. Therefore, the anti-obesity effect of G-hesperidin is incompletely understood.

Caffeine is one of the most widely consumed dietary components (e.g., tea, coffee) with pharmacological effects and psychostimulant activity. Caffeine has been reported to induce lipolysis of adipocytes \[[@CR20]\], fat oxidation \[[@CR21]\], energy expenditure \[[@CR22]\] and thermogenic responses \[[@CR23]\] in humans. However, caffeine has not been shown to reduce body fat in humans, so its effects upon fat metabolism are, in general, considered to be insignificant \[[@CR24]\].

We have shown before that combining food ingredients involved in lipid metabolism is useful for the prevention or treatment of obesity. For example, a mixture of thiamine, L-arginine, caffeine, and citric acid has been shown to have an anti-obesity effect in obese mice and humans with a high BMI \[[@CR25], [@CR26]\]. We have also shown that a combination of G-hesperidin and caffeine reduces accumulation of body fat through (at least in part) inhibition of hepatic lipogenesis, whereas G-hesperidin or caffeine alone show little effect on high-fat diet-induced obesity in mice \[[@CR27]\].

We conducted an exploratory trial to investigate the anti-obesity effects of a combination of G-hesperidin and caffeine in subjects with a BMI of 24--30 kg/m^2^ and serum levels of TG of 100--250 mg/dl at a potentially effective dose of G-hesperidin (500 mg) \[[@CR19]\] with that of caffeine (25, 50, or 75 mg) \[[@CR26]\].

Methods {#Sec2}
=======

Test samples {#Sec3}
------------

Composition of test samples is listed in Table [1](#Tab1){ref-type="table"}. The base tablet comprised lactose, cornstarch, hard starch, and sugar ester. Lactose was substituted by G-hesperidin and caffeine. G-hesperidin was provided from Hayashibara (Okayama, Japan) and contained monoglucosyl hesperidin (\>75.0 %) and non-glycosylated hesperidin (\<25.0 %), which was confirmed by high-performance liquid chromatography. Caffeine (purity, \>98.5 %), extracted from coffee beans, was purchased from Shiratori Pharmaceuticals (Chiba, Japan).Table 1Composition of test samples (3 tablets/1 g)PlaceboGHGH + Caf 25GH + Caf 50GH + Caf 75Energy (kcal)4.054.014.014.014.01Protein (g)00000Fat (g)0.030.030.030.030.03Carbohydrate (g)0.940.930.930.930.93Glucosyl hesperidin (mg)0500500500500Caffeine (mg)00255075*GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mg

Subjects {#Sec4}
--------

A total of 160 Japanese people subjects were evaluated for eligibility. Screening led to a study cohort of 38 men and 37 women (20--65 years) with a moderately high BMI (24--30 kg/m^2^) and serum level of TG (100--250 mg/dL). Exclusion criteria were patients who had (i) ingested medicines and/or health-foods that might affect obesity and serum levels of TG or (ii) consumed many beverages containing caffeine (e.g. tea, green tea, coffee, and cola). From the results of a pre-questionnaire, daily caffeine consumption of each group was estimated as G-hesperidin, 112 ± 104 mg/day; G-hesperidin with 25-mg caffeine, 111 ± 76 mg/day; G-hesperidin with 50-mg caffeine, 89 ± 86 mg/day; G-hesperidin with 75-mg caffeine, 145 ± 104 mg/day; and placebo, 112 ± 84 mg/day.

Trial design {#Sec5}
------------

This trial was carried out from April to August 2013 on subjects at Fukuhara Clinic (Hokkaido, Japan) and complied with the Declaration of Helsinki. The study protocol was approved by the Ethics Review Board of Miyawaki Orthopedic Clinic (Hokkaido, Japan). Procedures were explained fully to subjects. Written informed consent was obtained from each subject before study commencement.

This was a randomised, double-blind placebo-controlled trial comprising periods of pre-checking (1 week), eligibility assessment (4 weeks), intervention (12 weeks), and post-ingestion (4 weeks).

After assessment of eligibility, 75 subjects were allocated into five groups: 500-mg G-hesperidin; 500-mg G-hesperidin with 25-mg caffeine; 500-mg G-hesperidin with 50-mg caffeine; 500-mg G-hesperidin with 75-mg caffeine; placebo (Fig. [1](#Fig1){ref-type="fig"}). Allocation was by stratified randomisation based on age, sex, and waist circumference.Fig. 1Study flowchart. *GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mg

Intervention {#Sec6}
------------

Subjects ingested test samples as tablets (Table [1](#Tab1){ref-type="table"}) every day for 12 weeks. Time of ingestion of the test sample was not dictated to patients, but was recommended to be in the morning. Ingestion of large quantities of caffeine was prohibited. Ingestion of health-foods that influence levels of TG or cholesterol, or that affect obesity, was prohibited. Use of drugs for prolonged periods and use of drugs that interact with caffeine was banned. However, if a subject had been instructed to use a drug by his/her physician, he/she reported its name, dose, period, and indication. Dieting, drinking excessive amounts of alcohol, and intake of medicines known to affect lipid metabolism was prohibited. Subjects were instructed to maintain their regular lifestyle, in particular in relation to meal size and amount of exercise.

After assessment of eligibility, subjects visited the clinic five times at 4-week intervals. Subjects were prohibited from eating and drinking except for water from 9 pm the day before their visit until all checkups had been completed.

At the day of the visit, subjects underwent a physical examination, and analyses of blood and urine were conducted. The diet record, walking record, and diary were submitted at this time. At week 0 and week 12, the abdominal fat area (AFA) was measured.

Measurement of AFA {#Sec7}
------------------

Umbilical AFA was measured using a computed tomography system (CT-W450; Hitachi Medical Corporation, Tokyo, Japan) in accordance with the method described by Tokunaga et al. \[[@CR28]\]. Total fat area (TFA), visceral fat area (VFA), and subcutaneous fat area (SFA) were computed using Fat Scan™ v3.0 (N2 systems, Osaka, Japan).

Safety assessment {#Sec8}
-----------------

Haematological assessments (counts of white blood cells, red blood cells and platelets, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration), blood biochemical assessment (total protein, albumin, total bilirubin, aspartate aminotransferase, alanine transaminase, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transferase, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), TG, glucose, uric acid, urea nitrogen, creatinine, Na^+^, K^+^, Cl^--^, Hb~A1c~), and urine analyses (specific gravity, pH, protein, sugar, urobilinogen, bilirubin, ketone bodies, occult blood reaction) were conducted at Daiichi-Kishimoto Clinical Laboratory (Sapporo, Japan). Anthropometric measurements were undertaken at Fukuhara Clinic.

Diet and walking surveys {#Sec9}
------------------------

During the intervention period and post-ingestion period, subjects photographed all the meals (including snacks) that they had consumed and recorded their contents in a diet questionnaire for 3 days before the checkup. A nutritionist calculated values of energy, protein, lipid, and carbohydrate using Excel Eiyokun™ v6.0 (Kenpakusha, Tokyo, Japan) from the diet questionnaires and photographs. During the same 3 days as diet recording, the number of steps was documented (using a pedometer) as the exercise volume.

Subject diaries {#Sec10}
---------------

During the intervention period and post-ingestion period, subjects recorded the time of ingestion of the test sample and subjective symptoms in their diaries.

Statistical analyses {#Sec11}
--------------------

Values are the mean ± SD. Comparison between baseline (week 0) and each time-point in each group was done by the paired *t*-test with multiple corrections except for AFA. After checking the equality of variance by the Bartlett method, comparisons between groups were analysed by Dunnett's method in the case of equal variance, and by Steel's method in the case of unequal variance. Analyses were performed using SAS v9.3 (SAS Institute, Cary, NC, USA), and *p* \< 0.05 was considered significant.

Results {#Sec12}
=======

Baseline characteristics of study participants {#Sec13}
----------------------------------------------

Seventy-five subjects completed the study. However, one subject who completed the study with a major violation of the test protocol owing to bereavement was excluded from efficacy analyses. The baseline (week 0) characteristics of 74 subjects are listed in Table [2](#Tab2){ref-type="table"}. No significant difference was observed in baseline (week 0) characteristics between groups. Safety analyses were conducted in all 75 subjects. The study flowchart is shown in Fig. [1](#Fig1){ref-type="fig"}.Table 2Subjects' baseline characteristicsPlaceboGHGH + Caf 25GH + Caf 50GH + Caf 75Subject (Men/women)N = 14 (7/7)n = 15 (7/8)n = 15 (8/7)n = 15 (8/7)n = 15 (7/8)Age (y)49.4 ± 8.549.0 ± 1049.1 ± 1350.8 ± 9.847.3 ± 9.9Height (cm)163.7 ± 11162.9 ± 9.7162.0 ± 8.9162.6 ± 8.4162.6 ± 7.3Body weight (g)70.3 ± 9.670.0 ± 9.969.2 ± 9.070.5 ± 7.470.2 ± 6.5BMI (kg/m^2^)26.1 ± 1.126.2 ± 1.626.3 ± 1.226.7 ± 1.826.5 ± 1.2Waist (cm)90.9 ± 5.790.6 ± 3.090.4 ± 5.390.0 ± 4.791.0 ± 4.4Hip (cm)96.5 ± 5.196.8 ± 2.995.9 ± 4.497.1 ± 3.196.4 ± 4.6Abdominal fat area Total (cm^2^)301.7 ± 50.6304.3 ± 41.8297.9 ± 54.8295.1 ± 53.7310.8 ± 43.9 Visceral (cm^2^)97.2 ± 53.197.6 ± 27.7107.5 ± 42.3108.1 ± 46.1101.1 ± 28.9 Subcutaneous (cm^2^)204.6 ± 59.5206.6 ± 45.4190.4 ± 59.0187.0 ± 48.0209.8 ± 45.4*GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mg, *BMI* Body Mass IndexMean ± SD

Ingestion of test samples {#Sec14}
-------------------------

Percentage of patients who ingested test samples in the placebo group, 500-mg G-hesperidin group, 500-mg G-hesperidin with 25-mg caffeine group, 500-mg G-hesperidin with 50-mg caffeine group, and 500-mg G-hesperidin with 75-mg caffeine group was 99.4, 99.6, 99.8, 99.8, and 99.8 %, respectively.

Energy intake and exercise volume {#Sec15}
---------------------------------

Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table [3](#Tab3){ref-type="table"}. Occasionally, significant differences were found within groups, but there was no significant difference between groups.Table 3Dietary composition and exercise volume during intervention period and post- ingestion periodIntervention periodPost-ingestion periodItemGroupnWeek-0Week-4Week-8Week-12Week-16Energy (kcal/3d)Placebo146075 ± 13365925 ± 9345648 ± 1108\*\*5623 ± 8725488 ± 924\*GH155599 ± 13875748 ± 15005383 ± 12505322 ± 12595328 ± 1013GH + Caf 25155606 ± 12705512 ± 10315252 ± 13404981 ± 12915155 ± 1395GH + Caf 50155240 ± 14635774 ± 16665425 ± 15385302 ± 17235272 ± 1635GH + Caf 75155727 ± 9295268 ± 13695546 ± 13025119 ± 15385401 ± 1618Exercise volume (step/3d)Placebo1421661 ± 1216222372 ± 936627058 ± 1173525258 ± 1024723994 ± 10039GH1517118 ± 780922161 ± 1503319231 ± 867722738 ± 11305\*20298 ± 8622GH + Caf 251519929 ± 867922946 ± 1441222350 ± 1617219656 ± 1685522996 ± 14817GH + Caf 501523513 ± 1315621881 ± 1215722491 ± 991123005 ± 1252424650 ± 12288GH + Caf 751518843 ± 745519828 ± 653224016 ± 870324036 ± 948823972 ± 8216*GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mgData are the mean ± SD recorded 3 days before each check-up\**p* \< 0.05, \*\**p* \< 0.01 vs. baseline (week-0), (paired t-test)

Effect of a combination of G-hesperidin and caffeine upon obesity {#Sec16}
-----------------------------------------------------------------

Measurement at week 0 and week 12 as well as change from the baseline (week 0) in AFA is shown in Table [4](#Tab4){ref-type="table"}. Furthermore, changes from baseline are also represented in Fig. [2](#Fig2){ref-type="fig"}. Decreases in TFA in the G-hesperidin with 50-mg caffeine group and in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group. Degree of decrease of TFA appeared to be enhanced in a caffeine dose-dependent manner. Decreases in SFA in the G-hesperidin with 50-mg caffeine group and G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group. However, there were no significant decreases in VFA between the placebo group and groups that ingested G-hesperidin with or without caffeine.Table 4Effect of G-hesperidin + caffeine tablets on abdominal fat areaParameterGroupnWeek-0Week-12Change from baselineTotal fat area (cm^2^)Placebo14301.7 ± 50.6318.1 ± 50.416.3 ± 34.1GH15304.3 ± 41.8299.7 ± 44.1−4.6 ± 20.5GH + Caf 2515297.9 ± 54.8293.7 ± 61.5−4.2 ± 18.2GH + Caf 5015295.1 ± 53.7286.7 ± 48.9−8.4 ± 21.9^\#^GH + Caf 7515310.8 ± 43.9293.9 ± 45.5−17.0 ± 31.4^\#\#^Visceral fat area (cm^2^)Placebo1497.2 ± 53.1102.3 ± 61.95.1 ± 25.9GH1597.6 ± 27.796.6 ± 27.5−1.1 ± 15.0GH + Caf 2515107.5 ± 42.3103.6 ± 40.0−3.8 ± 14.5GH + Caf 5015108.1 ± 46.1109.0 ± 46.60.9 ± 11.3GH + Caf 7515101.1 ± 28.996.5 ± 33.7−4.5 ± 16.1Subcutaneous fat area (cm^2^)Placebo14204.6 ± 59.5215.8 ± 63.5\*11.2 ± 18.3GH15206.6 ± 45.4203.1 ± 44.2−3.5 ± 11.8GH + Caf 2515190.4 ± 59.0190.1 ± 60.1−0.4 ± 14.3GH + Caf 5015187.0 ± 48.0177.7 ± 44.0−9.3 ± 17.1^\#\#^GH + Caf 7515209.8 ± 45.4197.3 ± 44.4\*−12.4 ± 18.7^\#\#^*GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mgMean ± SD, \**p* \< 0.05 *vs*. baseline (week-0), (paired *t*-test), ^\#^p \< 0.05, ^\#\#^p \< 0.01 *vs*. placebo Fig. 2Change in abdominal fat area after 12 weeks of intervention. Data are expressed as Mean ± SD. ♯:*p* \< 0.05, ♯♯:*p* \< 0.01 v.s. Placebo. *n* = 15 in each of groups except for Placebo (*n* = 14). *GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mg

Measurements during and after the intervention period as well as changes from baseline (week 0) in body weight, the BMI, and circumferences of the waist and hip are shown in Table [5](#Tab5){ref-type="table"}. Decreases in body weight at week 8 (*p* = 0.045) but not at week 12 (*p* = 0.089) were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group. Decreases in the BMI in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group at week 8 and week 12. The BMI-decreasing effect of G-hesperidin appeared to be enhanced dose-dependently by caffeine addition. Decreases in waist circumference were significantly greater in the G-hesperidin with 25 mg caffeine group than in the placebo group at week-8 and at week-12. Similar decreases were observed in the G-hesperidin with 75 mg caffeine group but were not significant. There were no significant differences in decreases in hip circumference between the placebo group, and groups that ingested G-hesperidin with or without caffeine.Table 5Anthropometric variables during the intervention period and post- ingestion periodsIntervention periodpost- ingestion periodParameterGroupnWeek-0Week-4Week-8Week-12Week-16Body weight (kg)Placebo1470.3 ± 9.670.1 ± 9.270.6 ± 9.070.1 ± 8.870.5 ± 9.3GH1570.0 ± 9.969.5 ± 9.769.9 ± 9.769.6 ± 9.470.0 ± 9.7GH + Caf 251569.2 ± 9.069.1 ± 9.068.8 ± 9.268.6 ± 9.568.7 ± 9.5GH + Caf 501570.5 ± 7.470.2 ± 7.570.1 ± 7.769.8 ± 7.769.8 ± 8.0GH + Caf 751570.2 ± 6.569.8 ± 6.669.3 ± 6.968.8 ± 7.068.9 ± 7.0ΔBody weight (kg)Placebo14−0.26 ± 1.10.24 ± 1.2−0.19 ± 1.70.16 ± 1.7GH15−0.44 ± 1.0−0.09 ± 0.9−0.39 ± 1.10.08 ± 1.4GH + Caf 2515−0.11 ± 0.8−0.39 ± 1.0−0.57 ± 1.1−0.48 ± 1.7GH + Caf 5015−0.29 ± 1.1−0.44 ± 1.3−0.67 ± 1.4−0.67 ± 1.8GH + Caf 7515−0.36 ± 1.0−0.88 ± 1.4^\#^−1.43 ± 2.0−1.27 ± 2.2BMI (kg/m^2^)Placebo1426.1 ± 1.126.1 ± 1.226.3 ± 1.126.1 ± 1.326.2 ± 1.2GH1526.2 ± 1.626.1 ± 1.626.2 ± 1.626.1 ± 1.626.3 ± 1.6GH + Caf 251526.3 ± 1.226.2 ± 1.326.1 ± 1.326.0 ± 1.426.1 ± 1.6GH + Caf 501526.7 ± 1.826.6 ± 1.826.5 ± 1.926.4 ± 1.926.4 ± 2.0GH + Caf 751526.5 ± 1.226.4 ± 1.326.2 ± 1.325.9 ± 1.3\*26.0 ± 1.3ΔBMI (kg/m^2^)Placebo14−0.07 ± 0.370.14 ± 0.39−0.02 ± 0.580.08 ± 0.57GH15−0.15 ± 0.36−0.01 ± 0.38−0.13 ± 0.420.03 ± 0.53GH + Caf 2515−0.05 ± 0.31−0.14 ± 0.40−0.23 ± 0.40−0.19 ± 0.65GH + Caf 5015−0.13 ± 0.42−0.19 ± 0.52−0.28 ± 0.56−0.27 ± 0.70GH + Caf 7515−0.13 ± 0.41−0.35 ± 0.55^\#^−0.56 ± 0.74^\#^−0.51 ± 0.84Waist (cm)Placebo1490.9 ± 5.790.7 ± 5.591.1 ± 5.191.3 ± 4.891.3 ± 5.3GH1590.6 ± 3.090.6 ± 3.590.6 ± 3.490.6 ± 3.390.6 ± 3.8GH + Caf 251590.4 ± 5.389.9 ± 5.989.3 ± 6.0\*89.1 ± 6.2\*89.5 ± 6.4GH + Caf 501590.0 ± 4.789.6 ± 5.089.7 ± 5.289.1 ± 5.888.8 ± 6.5GH + Caf 751591.0 ± 4.491.0 ± 3.990.3 ± 4.089.9 ± 3.589.8 ± 3.1ΔWaist (cm)Placebo14−0.12 ± 0.90.19 ± 1.40.44 ± 20.42 ± 2.1GH150.01 ± 1.0−0.01 ± 1.4−0.02 ± 1.3−0.03 ± 1.3GH + Caf 2515−0.49 ± 1.1−1.17 ± 1.4^\#^−1.31 ± 1.6^\#^−0.96 ± 2.2GH + Caf 5015−0.31 ± 1.1−0.28 ± 1.3−0.82 ± 1.9−1.12 ± 2.6GH + Caf 75150.05 ± 1.0−0.66 ± 0.9−1.11 ± 1.7−1.21 ± 2.2Hip (cm)Placebo1496.5 ± 5.196.3 ± 5.396.5 ± 5.196.9 ± 5.597.1 ± 5.6GH1596.8 ± 2.996.6 ± 2.896.9 ± 2.896.4 ± 3.196.6 ± 2.8GH + Caf 251595.9 ± 4.496.1 ± 4.096.1 ± 4.096.0 ± 4.596.0 ± 5.0GH + Caf 501597.1 ± 3.196.8 ± 3.297.0 ± 3.297.0 ± 3.597.0 ± 3.4GH + Caf 751596.4 ± 4.696.2 ± 4.696.0 ± 4.695.5 ± 4.595.6 ± 4.6ΔHip (cm)Placebo14−0.17 ± 0.70.01 ± 1.10.37 ± 1.60.64 ± 1.4GH15−0.17 ± 0.80.05 ± 1.3−0.41 ± 1.2−0.23 ± 1.5GH + Caf 25150.23 ± 0.80.17 ± 1.00.13 ± 1.40.06 ± 2.0GH + Caf 5015−0.26 ± 0.8−0.11 ± 1.3−0.08 ± 1.7−0.13 ± 2.0GH + Caf 7515−0.21 ± 1.0−0.39 ± 1.2−0.85 ± 1.8−0.79 ± 2.0*GH* glucosyl hesperidin 500 mg, *Caf 25, 50, 75* caffeine 25 mg, 50 mg, 75 mg, *BMI* Body Mass IndexMean ± SD, \**p* \< 0.05, *vs*. baseline (week-0), (paired *t*-test), ^\#^p \< 0.05 *vs*. placebo (Dunnett's test or Steel's test)

Effect of a combination of G-hesperidin and caffeine on serum levels of lipids {#Sec17}
------------------------------------------------------------------------------

Measurements during and after the intervention period as well as changes from baseline (week 0) in serum levels of TG, total cholesterol, HDL-C and LDL-C are shown in Table [6](#Tab6){ref-type="table"}. G-hesperidin has been reported to lower the serum levels of TG in subjects with moderately high levels of TG in serum \[[@CR17]\]. However, TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group. TG levels in the G-hesperidin with caffeine group also did not decrease. Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.Table 6Blood biochemical parameters during the intervention period and post- ingestion periodIntervention periodpost- ingestion periodParameterStandard valueGroupnWeek-0Week-4Week-8Week-12Week-16Triglyceride (mg/dl)50 \~ 149Placebo14144 ± 65142 ± 43131 ± 55141 ± 61119 ± 44GH15128 ± 55132 ± 49134 ± 71153 ± 70152 ± 58GH + Caf 2515126 ± 48137 ± 53135 ± 47129 ± 36127 ± 47GH + Caf 5015133 ± 70137 ± 29136 ± 50148 ± 66144 ± 54GH + Caf 7515156 ± 74136 ± 35127 ± 40134 ± 39135 ± 41ΔTriglyceride (mg/dl)Placebo14−1.4 ± 58−12.4 ± 49−2.6 ± 57−24.9 ± 50GH154.3 ± 335.5 ± 4624.6 ± 6024.0 ± 47GH + Caf 251511.1 ± 498.9 ± 513.0 ± 441.0 ± 46GH + Caf 50154.4 ± 692.9 ± 7015.3 ± 4510.7 ± 54GH + Caf 7515−21.9 ± 80−29.3 ± 66−22.7 ± 61−21.3 ± 74Total cholesterol (mg/dl)150 \~ 219Placebo14220 ± 37216 ± 44215 ± 39220 ± 39219 ± 45GH15229 ± 29217 ± 29\*224 ± 29224 ± 30222 ± 28GH + Caf 2515213 ± 27210 ± 24202 ± 30205 ± 26205 ± 31GH + Caf 5015222 ± 34218 ± 37216 ± 34222 ± 34219 ± 40GH + Caf 7515241 ± 27228 ± 31225 ± 27\*227 ± 24\*233 ± 23ΔTotal cholesterol (mg/dl)Placebo14−4.8 ± 20−5.2 ± 16−0.1 ± 18−1.9 ± 24GH15−12.5 ± 17−5.3 ± 15−5.8 ± 14−7.6 ± 16GH + Caf 2515−3.3 ± 17−11.3 ± 21−8.2 ± 16−8.5 ± 17GH + Caf 5015−4.5 ± 16−6.1 ± 180 ± 15−3.2 ± 22GH + Caf 7515−5.3 ± 22−15.5 ± 21−13.1 ± 14−7.6 ± 22HDL-cholesterol (mg/dl)Men:Placebo1454.6 ± 1251.8 ± 1051.5 ± 1251.8 ± 1153.0 ± 1240 \~ 80GH1553.9 ± 1051.8 ± 1052.3 ± 950.9 ± 951.7 ± 9Women:GH + Caf 251553.9 ± 1153.4 ± 1349.3 ± 10\*\*49.9 ± 11\*\*50.9 ± 1040 \~ 90GH + Caf 501553.6 ± 1151.5 ± 949.7 ± 650.1 ± 851.7 ± 8GH + Caf 751556.5 ± 1155.9 ± 1255.0 ± 1254.3 ± 1155.1 ± 10ΔHDL-cholesterol (mg/dl)Placebo14−2.8 ± 6.2−3.1 ± 4.7−2.8 ± 5.0−1.6 ± 5.6GH15−2.1 ± 5.4−1.6 ± 4.4−3.0 ± 5.6−2.1 ± 4.8GH + Caf 2515−0.5 ± 4.9−4.6 ± 4.4−4.0 ± 3.9−3.1 ± 4.4GH + Caf 5015−2.1 ± 5.1−3.9 ± 7.1−3.5 ± 4.8−1.9 ± 8.2GH + Caf 7515−0.3 ± 6.7−1.5 ± 6.4−2.2 ± 5.7−1.4 ± 5.8LDL-cholesterol (mg/dl)70 \~ 139Placebo14147 ± 41142 ± 44145 ± 40144 ± 39148 ± 47GH15151 ± 29140 ± 24148 ± 30140 ± 30\*144 ± 25GH + Caf 2515140 ± 30137 ± 20134 ± 27133 ± 25134 ± 27GH + Caf 5015149 ± 37147 ± 40147 ± 36148 ± 36147 ± 37GH + Caf 7515161 ± 28155 ± 29152 ± 19149 ± 21160 ± 24ΔLDL-cholesterol (mg/dL)Placebo14−5.6 ± 17−2.4 ± 15−2.8 ± 160.9 ± 21GH15−11.0 ± 17−3.1 ± 15−10.6 ± 14−7.5 ± 14GH + Caf 2515−2.6 ± 21−5.9 ± 18−7.5 ± 14−5.9 ± 15GH + Caf 5015−2.7 ± 16−2.3 ± 18−1.0 ± 14−2.8 ± 15GH + Caf 75151.1 ± 31−8.9 ± 20−12.2 ± 21−1.5 ± 23GH glucosyl hesperidin 500 mg, Caf 25, 50, 75, caffeine 25 mg, 50 mg, 75 mg, BMI Body Mass Index, LDL low-density lipoprotein, HDL high-density lipoproteinMean ± SD \**p* \< 0.05, \*\**P* \< 0.01 vs. baseline (week 0) (paired t-test)

Safety assessment {#Sec18}
-----------------

Twenty-nine adverse events (AEs) were recorded during the study. Of the seven AEs in the placebo group, three were symptoms of a common cold, one was a pollen allergy, one was pain, one was tinnitus, and one was sudden deafness. Of the six AEs in the G-hesperidin group, three were symptoms of a common cold, two were pain, and one was conjunctivitis. Of the five AEs in the G-hesperidin with 25 mg caffeine group, two were symptoms of a common cold, two were digestive symptoms, and one was pain. Of the eight AEs in the G-hesperidin with 50-mg caffeine group, three were digestive symptoms, one was a symptom of a common cold, one was pain, one was a pollen allergy, one was fatigue, and one was irritation. Of three AEs in the G-hesperidin with 75-mg caffeine group, one was a symptom of common cold, one was pain, and one was a pollen allergy. Of the 29 AEs, one was moderate and 28 were mild. All AEs were judged to be unrelated to the dietary intervention, in which the moderate AE of sudden deafness was considered to be a result of the stress of bereavement.

Among the safety assessments undertaken, total protein in serum at week 4 in the G-hesperidin with 25 mg caffeine group (7.24 ± 0.23 g/dl) or at week 8 in the G-hesperidin with 75 mg caffeine group (7.27 ± 0.39 g/dl) were significantly greater than in the placebo group (week 4: 6.94 ± 0.19 g/dl, week 8: 7.27 ± 0.39 g/dl), and urine gravity at week 4 in the G-hesperidin with 75 mg caffeine group (1.013 ± 0.004 g/ml) was significantly lower than in the placebo group (1.018 ± 0.006 g/ml). However, these changes were within the ranges of corresponding reference values.

Discussion {#Sec19}
==========

We conducted a randomised double-blind placebo-controlled study to evaluate the anti-obesity effect and serum TG-lowering effect of a combination of G-hesperidin and caffeine in subjects with a moderately high BMI and moderately high serum levels of TG.

Intake of G-hesperidin with 50-mg caffeine and 75-mg caffeine showed significant decreasing effects on AFA (especially on SFA). This fat-decreasing effect seemed to be enhanced by the dose-dependent addition of caffeine. Significant decreases in body weight and the BMI were observed in the G-hesperidin with 75-mg caffeine group compared with those in the placebo group. Decreases in VFA in G-hesperidin with caffeine groups were not significant compared with those in the placebo group. Visceral adipose tissue has been proposed to mediate obesity-related unfavourable levels of insulin, glucose and lipids, but subcutaneous abdominal adipose tissue has been shown to be independent risk factor for the metabolic complications of obesity \[[@CR29]--[@CR31]\]. Therefore, our observations that a combination of G-hesperidin and caffeine decreased AFA may have clinical significance.

We have developed anti-obesity agents containing dietary components that affect lipid metabolism. Their effectiveness has been evaluated in non-insulin-dependent diabetic KK mice induced to develop obesity by feeding with a high-fat diet. Among the agents examined in this model, a mixture of thiamine, arginine, caffeine, and citric acid, as well as a mixture of arginine, caffeine, soy isoflavones and carnitine, have shown prominent anti-obesity effects \[[@CR25], [@CR32]\]. Recently, we have shown that a combination of G-hesperidin and caffeine decreased weights of subcutaneous fat and visceral fat effectively in high-fat diet-induced obese mice \[[@CR27]\]. We consider the mechanism of its anti-obesity effect is partially through the inhibition of hepatic lipogenesis (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR27]\]. In addition to the effectiveness of a mixture of thiamine, arginine, caffeine and citric acid in the treatment of obesity in humans \[[@CR26]\], we showed an anti-obesity effect of a combination of G-hesperidin and caffeine in moderately obese subjects in the present study. Therefore, the effectiveness of anti-obesity agents comprising dietary components observed in obese KK mice can be expected to have a similar effect in humans.Fig. 3Fat-reducing effect of the combination of G-hesperidin and caffeine is partially through the inhibition of hepatic lipogenesis. G6P, Glucose-6-phosphate; G6PD, Glucose-6-phosphate dehydrogenase; ACC, Acetyl-CoA carboxylase; FAS, Fatty acid synthase; VLDL, very low density lipoprotein

Reports have shown that 12-week intake of G-hesperidin (500 mg) lowers serum levels of TG in subjects with moderately high levels of TG in serum \[[@CR17]\]. In contrast to those observations, intake of G-hesperidin with or without caffeine had no effect on serum levels of TG in subjects with moderately high levels of TG. Unlike previous studies, we recruited subjects with a moderately high BMI in addition to a moderately high level of TG. It has been reported that plasma levels of TG in obese subjects do not decrease efficiently in response to insulin, are overproduced, or are resistant to clearance \[[@CR33]\]. Such changes in TG metabolism in obese subjects may affect the action of G-hesperidin, leading to the slight effect of G-hesperidin on serum levels of TG in obese subjects.

In the present study, mean daily consumption of caffeine other than during intervention was about 100 mg in subjects of each group. Nevertheless, a dose--response of caffeine from 25 mg to 75 mg was observed in the anti-obesity effects of this combination. Hence, concomitant (but not habitual) intake of caffeine with G-hesperidin might be important for the anti-obesity activity of this combination. Indeed, in studies demonstrating the anti-obesity effect of caffeine-containing components, caffeine was taken concomitantly with other ingredients \[[@CR34], [@CR35]\]. If concomitant intake is important, then whether single intake of such a low dose of caffeine has physiological relevance is of particular importance. It has been reported that a single dose of 12.5 mg caffeine affects cognitive performance \[[@CR36]\] and that 32-mg caffeine improves auditory vigilance and visual reaction time \[[@CR37]\]. Therefore, concomitant intake of caffeine may have physiological activity and synergize with G-hesperidin. Further investigations are required to clarify the importance of concomitant intake of caffeine and G-hesperidin.

Conclusions {#Sec20}
===========

Our results showed that intake of a combination of 500-mg G-hesperidin and 75-mg caffeine for 12 weeks significantly reduced abdominal fat (especially subcutaneous fat), body weight and the BMI in subjects with a moderately high BMI. Therefore, a combination of G-hesperidin and caffeine may be useful for the prevention or treatment of obesity.

AFA

:   abdominal fat area

BMI

:   body mass index

G-hesperidin

:   glucosyl hesperidin

TG

:   triglyceride
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